Resources Repository
-
ArticlePublication 2021Alleviating the Burden of Diabetes with Health Equity Funds: Economic Evaluation of the Health & Financial Risk Protection Benefits in Cambodia
This study examines the potential distributional health and financial impacts of implementing strategies to provide …
This study examines the potential distributional health and financial impacts of implementing strategies to provide financial coverage for diabetes services through Health Equity Funds (HEF) in Cambodia. Utilizing a Markov model, the trajectory of diabetes is projected over a 45-year period to estimate societal costs, health outcomes, and individual out-of-pocket expenditures associated with six HEF coverage strategies. Input parameters are derived from published literature and household survey data. Strategies covered different combinations of types of…
Health Outcomes | Chronic Disease/Risk | Mathematical Models | Cost-Effectiveness Analysis | Health/Medicine | Asia & Pacific -
ArticlePublication 2019Cost-Effectiveness of Community-Based Childhood Obesity Prevention Interventions in Australia
This study examined the cost-effectiveness of community-based obesity prevention interventions (CBIs) consisting of strategies to …
This study examined the cost-effectiveness of community-based obesity prevention interventions (CBIs) consisting of strategies to promote healthy eating and physical activity for Australian children aged between 5-18 years. A multiple cohort Markov model that simulates diseases associated with overweight and obesity was used to estimate the health benefits, measured as health-adjusted life years (HALYs) and healthcare-related cost offsets from diseases averted due to exposure to the intervention. Health and cost outcomes were estimated over the…
Health Outcomes | Chronic Disease/Risk | State-Transition | Cost-Effectiveness Analysis | Child/Nutrition | Health Systems | Clinical Care | Food/Agriculture | Health/Medicine | Oceania -
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Evidence Synthesis | Chronic Disease/Risk | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | Global -
ArticlePublication 2017Simulation of Growth Trajectories of Childhood Obesity into Adulthood
The authors developed a simulation model to estimate the risk of adult obesity at the age …
The authors developed a simulation model to estimate the risk of adult obesity at the age of 35 years for the current population of children in the United States. They used pooled height and weight data from five nationally representative longitudinal studies totaling 176,720 observations from 41,567 children and adults to simulate growth trajectories across the life course adjusted for secular trends. Using 1,000 virtual populations of 1 million children through the age of 19 years, representative of the…
Health Outcomes | Chronic Disease/Risk | Microsimulation | Child/Nutrition | Health/Medicine | North America -
ArticlePublication 2017Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control
Based on data from the Systolic Blood Pressure Intervention Trial (SPRINT), the authors of this …
Based on data from the Systolic Blood Pressure Intervention Trial (SPRINT), the authors of this article compared the cost-effectiveness of intensive versus standard control in adults at high risk for cardiovascular disease who received intensive systolic blood-pressure control. A microsimulation model was used to project lifetime costs of treatment and monitoring, cardiovascular disease events and subsequent treatment costs, treatment-related risks of serious adverse events and subsequent costs, and quality-adjusted life-years (QALYs) for the two strategies.…
Health Outcomes | Chronic Disease/Risk | Microsimulation | Cost-Effectiveness Analysis | Health/Medicine | North America -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Test Performance | Chronic Disease/Risk | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | Global | North America -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Costing Methods | Chronic Disease/Risk | Priority Setting/Ethics | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
ReviewPublication 2017Patients' Preferences in Cancer Treatment: Review of Discrete Choice Experiments
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer …
This study aimed to systematically review discrete choice experiments (DCEs) about patients’ preferences for cancer treatment and assessed the relative importance of outcome, process and cost attributes. A systematic literature review was conducted using PubMed and EMBASE to identify all DCEs investigating patients’ preferences for cancer treatment between January 2010 and April 2016. Attributes were classified into outcome, process and cost attributes, and their relative importance was assessed. A total of 28 DCEs were identified.…
Health Outcomes | Chronic Disease/Risk | Preferences/Values | Decision Analysis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | North America | Europe -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Costing Methods | Chronic Disease/Risk | Benefit-Cost Analysis | Policy/Regulation | Government/Law | Health/Medicine | North America